(Reuters) - Europe's drugs regulator said on Tuesday it was expecting to give an opinion before the summer on whether Gilead Sciences' remdesivir can be used to treat COVID-19 patients who do not need oxygen support.
The indication for extended use, if approved, would allow the antiviral treatment to be given to more patients as coronavirus infections surge and healthcare systems are pressured by emerging, highly transmissible variants of the virus.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!